All In Biotech

Drug Trial Radar · NCT07064486

A Study of BGM0504 in Participants With Type 2 Diabetes in Indonesia

A Phase 3, Randomized, Open Label Trial Comparing Efficacy and Safety of BGM0504 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin in Patients With Type 2 Diabetes

Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 152 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

152

Actual

Start

Jul 4, 2025

Primary completion

Apr 30, 2027

Study completion Apr 30, 2027

Sponsor

Sponsor type
Industry
First posted
Jul 14, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This trial is conducted in Indonesia. The aim of the trial is to evaluate the efficacy and safety of BGM0504 versus semaglutide as add-on to metformin in patients with type 2 diabetes

Conditions

  • Type 2 Diabetes (T2DM)

Interventions

  • BGM0504Drug

    Administered SC

  • BGM0504Drug

    Administered SC

  • SemaglutideDrug

    Administered SC

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline in Hemoglobin A1c (HbA1c)Time frame: Week 0 to Week 24

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • RSUP Fatmawati

    Jakarta, Indonesia

  • RSUP Persahabatan

    Jakarta, Indonesia

  • RSUPN Dr. Cipto Mangunkusumo

    Jakarta, Indonesia

  • RS Universitas Indonesia

    Depok, West Java, Indonesia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.